CRISPR

In the late 1980s and mid-1990s, genomes of diverse lineages of bacteria and archaea (the latter representing a domain of single-celled prokaryotic microorganisms) revealed clusters of regularly interspaced short palindromic repeats, known today under the abbreviation CRISPR. Later it was found that these repeat sequences (previously considered disparate) share a common set of features.
CRISPR: Ethical and Safety Concerns

CRISPR and Cas proteins have become a crucial tool for genetic manipulation in biomedical research and biotechnology, and the crux of its action is the recognition of specific sequences in the DNA and their subsequent cleavage from the chain. One specific system, CRISPR-Cas9, has become the standard for genetic editing, since it can be tailored to target any set of DNA sequences. Thus it is of no wonder that it caused an upheaval in biomedical field.

Read More

Overview

Feature Articles

Latest CRISPR News and Research

Promising gene editing therapy shows hope in sickle cell disease cure

Promising gene editing therapy shows hope in sickle cell disease cure

Key protein orco crucial for ant olfactory neuron survival and social behavior

Key protein orco crucial for ant olfactory neuron survival and social behavior

Genetic discovery reveals key to inflammatory diseases

Genetic discovery reveals key to inflammatory diseases

Miniaturized CRISPR protein opens door for gene therapy with adeno-associated virus

Miniaturized CRISPR protein opens door for gene therapy with adeno-associated virus

Advancing therapeutic insights: The impact of understanding cellular target engagement with NanoBRET® technology

Advancing therapeutic insights: The impact of understanding cellular target engagement with NanoBRET® technology

Innovative startups leading the charge in alternative proteins to solve global food crisis

Innovative startups leading the charge in alternative proteins to solve global food crisis

Researchers decode spatial structure of prime editor

Researchers decode spatial structure of prime editor

Changing the landscape of R&D to build clinical success from the ground up

Changing the landscape of R&D to build clinical success from the ground up

Two new studies offer insights into the molecular biology of neuropsychiatric disease

Two new studies offer insights into the molecular biology of neuropsychiatric disease

New MOBE technology revolutionizes multiplexed genome editing

New MOBE technology revolutionizes multiplexed genome editing

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

New CRISPR screen method reveals cellular drivers of neurological disorders

New CRISPR screen method reveals cellular drivers of neurological disorders

Repurposing human-approved drugs for prion disease treatment

Repurposing human-approved drugs for prion disease treatment

New study finds Sfrp1 as a potential therapeutic target in cancer treatment

New study finds Sfrp1 as a potential therapeutic target in cancer treatment

Human cell-based model of thoracic aortic aneurysm offers new opportunities for drug development

Human cell-based model of thoracic aortic aneurysm offers new opportunities for drug development

Scientists unlock mystery behind a deadly strain of cholera bacteria

Scientists unlock mystery behind a deadly strain of cholera bacteria

ERS Genomics appoints John E Milad as Chief Executive Officer

ERS Genomics appoints John E Milad as Chief Executive Officer

New modular epigenome editing platform sheds light on gene regulation mechanisms

New modular epigenome editing platform sheds light on gene regulation mechanisms

Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness

Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.